In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our ...

There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (FOP) on the US market, but ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

UK-based electronRx will launch a digital health technology (DHT) to help patients with respiratory disease manage their ...

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as ...

The importance of AI in pharma and life sciences cannot be overstated. Regardless of the aspect of industry you examine, ...

Novo Nordisk is also ahead in the race to bring an oral GLP-1 to market for weight loss, as it has already filed semaglutide for FDA approval, with a decision before the end of this year, while Lilly ...